{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:55:57Z","timestamp":1790229357036,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00330-020-07554-6","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T17:03:01Z","timestamp":1606496581000},"page":"4166-4174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors"],"prefix":"10.1007","volume":"31","author":[{"given":"Nicolas","family":"Deleval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Pesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Dieudonn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Viry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Hentic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachida","family":"Lebtahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruszniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-9189","authenticated-orcid":false,"given":"Louis","family":"de Mestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"7554_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol"},{"key":"7554_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A et al (2012) ENETS Consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157\u2013176. https:\/\/doi.org\/10.1159\/000335597","journal-title":"Neuroendocrinology"},{"key":"7554_CR3","first-page":"184","volume":"44","author":"WG Meijer","year":"2003","unstructured":"Meijer WG, van der Veer E, Jager PL et al (2003) Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44:184\u2013191","journal-title":"J Nucl Med"},{"key":"7554_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-14-0119","volume":"4","author":"KV Van Loon","year":"2015","unstructured":"Van Loon KV, Zhang L, Keiser J et al (2015) Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect 4:9\u201317. https:\/\/doi.org\/10.1530\/EC-14-0119","journal-title":"Endocr Connect"},{"key":"7554_CR5","doi-asserted-by":"publisher","unstructured":"Scharf M, Petry V, Daniel H, Rinke A, Gress TM (2018) Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology 106:30\u201337. https:\/\/doi.org\/10.1159\/000457954","DOI":"10.1159\/000457954"},{"key":"7554_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0002-9343(85)90313-4","volume":"79","author":"EM Ross","year":"1985","unstructured":"Ross EM, Roberts WC (1985) The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 79:339\u2013354","journal-title":"Am J Med"},{"key":"7554_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4149\/BLL_2017_102","volume":"118","author":"R Zamborsky","year":"2017","unstructured":"Zamborsky R, Svec A, Kokavec M, Galbavy S (2017) Bone metastases in neuroendocrine tumors. Bratisl Lek Listy 118:529\u2013534. https:\/\/doi.org\/10.4149\/BLL_2017_102","journal-title":"Bratisl Lek Listy"},{"key":"7554_CR8","doi-asserted-by":"publisher","unstructured":"Kimura T (2018) Multidisciplinary approach for bone metastasis: a review. Cancers (Basel) 10:156. https:\/\/doi.org\/10.3390\/cancers10060156","DOI":"10.3390\/cancers10060156"},{"key":"7554_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1634\/theoncologist.2018-0085","volume":"23","author":"A Parkes","year":"2018","unstructured":"Parkes A, Warneke CL, Clifton K et al (2018) Prognostic factors in patients with metastatic breast cancer with bone-only metastases. Oncologist 23:1282\u20131288. https:\/\/doi.org\/10.1634\/theoncologist.2018-0085","journal-title":"Oncologist"},{"key":"7554_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.6061\/clinics\/2015(08)01","volume":"70","author":"B Y\u00fccel","year":"2015","unstructured":"Y\u00fccel B, Celasun MG, \u00d6ztoprak B et al (2015) The negative prognostic impact of bone metastasis with a tumor mass. Clinics (Sao Paulo) 70:535\u2013540. https:\/\/doi.org\/10.6061\/clinics\/2015(08)01","journal-title":"Clinics (Sao Paulo)"},{"key":"7554_CR11","unstructured":"Montravers F, Grahek D, Kerrou K et al (2006) Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 47:1455\u20131462"},{"key":"7554_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","volume":"26","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, Neels OC, Kema IP et al (2008) Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26:1489\u20131495. https:\/\/doi.org\/10.1200\/JCO.2007.15.1126","journal-title":"J Clin Oncol"},{"key":"7554_CR13","first-page":"1161","volume":"45","author":"A Becherer","year":"2004","unstructured":"Becherer A, Szab\u00f3 M, Karanikas G et al (2004) Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 45:1161\u20131167","journal-title":"J Nucl Med"},{"key":"7554_CR14","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1210\/jc.2008-1349","volume":"94","author":"F Montravers","year":"2009","unstructured":"Montravers F, Kerrou K, Nataf V et al (2009) Impact of fluorodihydroxyphenylalanine-(18F) positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 94:1295\u20131301. https:\/\/doi.org\/10.1210\/jc.2008-1349","journal-title":"J Clin Endocrinol Metab"},{"key":"7554_CR15","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S et al (2017) Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging 44:1588\u20131601. https:\/\/doi.org\/10.1007\/s00259-017-3728-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7554_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.dld.2020.02.011","volume":"52","author":"L de Mestier","year":"2020","unstructured":"de Mestier L, Lepage C, Baudin E et al (2020) Digestive neuroendocrine neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 52:473\u2013492. https:\/\/doi.org\/10.1016\/j.dld.2020.02.011","journal-title":"Dig Liver Dis"},{"key":"7554_CR17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","volume":"35","author":"V Ambrosini","year":"2008","unstructured":"Ambrosini V, Tomassetti P, Castellucci P et al (2008) Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 35:1431\u20131438. https:\/\/doi.org\/10.1007\/s00259-008-0769-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7554_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"Haug A, Auernhammer CJ, W\u00e4ngler B et al (2009) Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765\u2013770. https:\/\/doi.org\/10.1007\/s00259-008-1030-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7554_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","volume":"40","author":"S Balogova","year":"2013","unstructured":"Balogova S, Talbot J-N, Nataf V et al (2013) 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging 40:943\u2013966. https:\/\/doi.org\/10.1007\/s00259-013-2342-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7554_CR20","doi-asserted-by":"publisher","unstructured":"Ouvrard E, Chevalier E, Addeo P et al (2020) Intra-individual comparison of 18 F-FDOPA and 68 Ga-DOTATOC PET\/CT detection rate for metastatic assessment in patients with ileal neuroendocrine tumours. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.14312","DOI":"10.1111\/cen.14312"},{"key":"7554_CR21","volume-title":"Digestive system tumours","author":"WHO Classification of Tumours","year":"2019","unstructured":"WHO Classification of Tumours (2019) Digestive system tumours, 5th edn. IARC, Lyon","edition":"5"},{"key":"7554_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","volume":"252","author":"A Frilling","year":"2010","unstructured":"Frilling A, Sotiropoulos GC, Radtke A et al (2010) The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252:850\u2013856. https:\/\/doi.org\/10.1097\/SLA.0b013e3181fd37e8","journal-title":"Ann Surg"},{"key":"7554_CR23","doi-asserted-by":"publisher","first-page":"S-159","DOI":"10.1016\/S0016-5085(13)60572-7","volume":"144","author":"M Palazzo","year":"2013","unstructured":"Palazzo M, Zappa M, Lebtahi R et al (2013) Prognostic heterogeneity among patients with bone metastases from well-differentiated digestive neuroendocrine tumors. Gastroenterology 144:S-159. https:\/\/doi.org\/10.1016\/S0016-5085(13)60572-7","journal-title":"Gastroenterology"},{"key":"7554_CR24","doi-asserted-by":"publisher","unstructured":"Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC (2014) Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 120:2814\u20132823. https:\/\/doi.org\/10.1002\/cncr.28721","DOI":"10.1002\/cncr.28721"},{"key":"7554_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1530\/ERC-12-0340","volume":"20","author":"M Ter-Minassian","year":"2013","unstructured":"Ter-Minassian M, Chan JA, Hooshmand SM et al (2013) Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 20:187\u2013196. https:\/\/doi.org\/10.1530\/ERC-12-0340","journal-title":"Endocr Relat Cancer"},{"key":"7554_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378\u2013382. https:\/\/doi.org\/10.1038\/nrclinonc.2011.44","journal-title":"Nat Rev Clin Oncol"},{"key":"7554_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/RLU.0000000000000761","volume":"40","author":"GN Stormezand","year":"2015","unstructured":"Stormezand GN, Glaudemans AWJM, Slart RHJA (2015) (18)F-FDOPA accumulation in traumatic rib fractures: a potential pitfall. Clin Nucl Med 40:531\u2013532. https:\/\/doi.org\/10.1097\/RLU.0000000000000761","journal-title":"Clin Nucl Med"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-020-07554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-020-07554-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-020-07554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T19:12:34Z","timestamp":1621278754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-020-07554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["7554"],"URL":"https:\/\/doi.org\/10.1007\/s00330-020-07554-6","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Dr. Louis de Mestier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained (CEERB Paris Nord, IRB no 00006477-15-073).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 diagnostic or prognostic study\/observational\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}